文献速递精神分裂症与精神病性障碍

精神分裂症中苯丙胺诱导的纹状体多巴胺释放:激动剂放射性示踪剂研究

Amphetamine-Induced Striatal Dopamine Release Measured With an Agonist Radiotracer in Schizophrenia.
PubMed 文献 · Biol Psychiatry · 2017-12-07

该研究用D2/3激动剂示踪剂[11C]NPA PET测量14名未用药精神分裂症患者和14名匹配健康对照在基线及口服0.5 mg kg-1苯丙胺后的纹状体D2/3高亲和力受体结合,发现两组ΔBPND无差异,但苯丙胺显著加重患者阳性症状,提示突触后因素参与。

要点

  • 苯丙胺显著降低所有受试者纹状体[11C]NPA BPND,但患者与对照间ΔBPND无差异。
  • 苯丙胺显著增加精神分裂症患者阳性症状,但与[11C]NPA BPND或ΔBPND无相关。
  • 基线[11C]NPA BPND在患者与对照间仅呈趋势级增高(F1,26=3.34,p=.08)。

核心结论

  • 本研究在体内提示突触后因素参与精神分裂症中苯丙胺诱导的精神病性症状。

研究设计与样本

  • 研究纳入14名未用药精神分裂症患者和14名匹配健康对照,在基线及口服0.5 mg kg-1苯丙胺后行[11C]NPA PET测量纹状体BPND。

主要发现

  • 基线[11C]NPA BPND在精神分裂症与健康对照间呈趋势级增高(重复测量方差分析,F1,26=3.34,p=.08)。
  • 苯丙胺显著降低所有受试者所有纹状体区域的BPND。
  • 健康对照与精神分裂症患者间[11C]NPA ΔBPND无差异(重复测量方差分析,F1,26=1.9,p=.18)。
  • 苯丙胺显著增加精神分裂症患者阳性症状(19.5 ± 5.3 vs. 23.7 ± 4.1,配对t检验,p < .0001)。
  • 阳性症状变化与[11C]NPA BPND或ΔBPND无相关。

临床怎么用

  • 结果提示D2/3高亲和力受体状态可能不是苯丙胺诱导多巴胺释放差异的主要解释,临床解读需结合突触后机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Receptor imaging studies have reported increased amphetamine-induced dopamine release in subjects with schizophrenia (SCH) relative to healthy control subjects (HCs). A limitation of these studies, performed with D2/3 antagonist radiotracers, is the failure to provide information about D2/3 receptors configured in a state of high affinity for the agonists (i.e., D2/3 receptors coupled to G proteins [D2/3 HIGH]). The endogenous agonist dopamine binds with preference to D2/3 HIGH receptors relative to D2/3 LOW receptors, making it critical to understand the status of D2/3 HIGH receptors in SCH. METHODS: D2/3 agonist positron emission tomography radiotracer [11C]N-propyl-norapomorphine ([11C]NPA) binding potential (BPND) was measured in 14 off-medication subjects with SCH and 14 matched HCs at baseline and after the administration of 0.5 mg kg-1 oral D-amphetamine. The amphetamine-induced change in BPND (ΔBPND) was calculated as the difference between BPND in the postamphetamine condition and BPND in the baseline condition and was expressed as a percentage of BPND at baseline. RESULTS: A trend-level increase was observed in comparing baseline [11C]NPA BPND (repeated-measures analysis of variance, F1,26 = 3.34, p = .08) between the SCH and HC groups. Amphetamine administration significantly decreased BPND in all striatal regions across all subjects in both groups. No differences were observed in [11C]NPA ΔBPND (repeated-measures analysis of variance, F1,26 = 1.9, p = .18) between HCs and subjects with SCH. Amphetamine significantly increased positive symptoms in subjects with SCH (19.5 ± 5.3 vs. 23.7 ± 4.1, paired t test, p < .0001); however, no correlations were noted with [11C]NPA BPND or ΔBPND. CONCLUSIONS: This study provides in vivo indication of a role for postsynaptic factors in amphetamine-induced psychosis in SCH.

来源:Biol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Frankle WG, Paris J, Himes M, et al. Amphetamine-Induced Striatal Dopamine Release Measured With an Agonist Radiotracer in Schizophrenia. Biol Psychiatry. 2017. PMID: 29325847. doi:10.1016/j.biopsych.2017.11.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。